RCS - Allergy Therapeutics - ImmunoBON voted Most Innovative Product of 2021

Allergy TherapeuticsAnnouncement

16/09/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210916:nRSP9294La&default-theme=true

RNS Number : 9294L  Allergy Therapeutics PLC  16 September 2021

 

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

 

 

ImmunoBON voted Most Innovative Product of 2021 at Pharma Trend Image and
Innovation Awards in Germany

 

16 September 2021 Allergy Therapeutics (AIM: AGY), the fully integrated
commercial biotechnology pharmaceutical company specialising in allergy
vaccines, is pleased to announce that ImmunoBON, the Group's patented
protein-based oral product for the general treatment of allergies, has been
voted Most Innovative Product 2021 at the Pharma Trends Image and Innovation
Awards in Germany.

 

The awards, held every year, are based on the Pharma Trend benchmark study,
which seeks the views of 700 physicians, 100 pharmacists and 600 patients in
Germany.

 

ImmunoBON, which Allergy Therapeutics launched in Germany and Austria earlier
this year, replicates the reduced allergic reactions seen in people who live
on or close to livestock farms - the so called 'farm effect'. It offers an
innovative treatment approach for patients with mild allergies, the largest
segment of the allergy market.

 

Latest data support its use as a treatment for birch and house dust mite
allergies and Allergy Therapeutics is currently exploring its potential across
a broader patient population.

 

Manuel Llobet, CEO of Allergy Therapeutics, stated: "We are delighted that
ImmunoBON has been recognised for its innovative approach to the treatment of
allergy patients, particularly as the award is voted for by those we serve -
doctors, pharmacists and patients.

 

"ImmunoBON is an exciting product that provides an over the counter (OTC)
option which fits very well with our portfolio philosophy to develop highly
differentiated products with specific value added for our patients. Following
successful launches in Germany and Austria, we are looking forward to making
ImmunoBON available to more patients, through additional country launches, and
through research exploring its potential to treat additional allergies".

 

 

 

- ENDS -

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

 

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Carina Jurs

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

christina@sternir.com (mailto:christina@sternir.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company
focussed on the treatment and diagnosis of allergic disorders, including
aluminium free immunotherapy vaccines that have the potential to cure disease.
The Group sells proprietary and third-party products from its subsidiaries in
nine major European countries and via distribution agreements in an additional
ten countries. Its broad pipeline of products in clinical development includes
vaccines for grass, tree and house dust mite, and peanut allergy vaccine in
pre-clinical development. Adjuvant systems to boost performance of vaccines
outside allergy are also in development.

 

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is
headquartered in Worthing, UK with more than 11,000m(2) of state-of-the-art
MHRA-approved manufacturing facilities and laboratories. The Group, which has
achieved over 9% compound annual growth since formation, employs c.600
employees and is listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com) .

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAKZGMLGKNGMZZ